|
|
|
|
|
|
| Overview |
Valuation |
Financial |
Ownership |
Performance |
Technical |
Custom |
Charts |
Tickers |
Quotes |
Basic |
TA |
News |
Snapshot |
|
 |
| Total: 200 #1 |
Type: candle | line | technical Timeframe: daily |  |
|
 |
|
|
 |
| Market Cap | 11.42M | EPS (ttm) | -0.55 |
| P/E | - | EPS this Y | -257.31% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | -11.33% |
| P/S | 1.40 | EPS next 5Y | - |
| P/B | 0.35 | EPS Q/Q | 89.71% |
| Dividend | - | Sales Q/Q | 9.40% |
| Insider Own | 51.73% | Inst Own | 0.98% |
| Insider Trans | 0.50% | Inst Trans | -56.87% |
| Short Float | 0.00% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 0.79K | 52W Range | 2.07 - 5.00 |
|
|
| 03-Feb-10 09:00AM | ANNAPOLIS BANCORP INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online |
| 03-Feb-10 09:00AM | Annapolis Bancorp Earnings Increase in Fourth Quarter of 2009 Business Wire |
| 25-Nov-09 02:05PM | BankAnnapolis adds to executive team at bizjournals.com |
| 18-Nov-09 09:04AM | ANNAPOLIS BANCORP INC Financials EDGAR Online Financials |
| 13-Nov-09 09:16AM | ANNAPOLIS BANCORP INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 02-Nov-09 09:00AM | ANNAPOLIS BANCORP INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online |
| 12-Aug-09 04:56PM | ANNAPOLIS BANCORP INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 15-May-09 04:02PM | ANNAPOLIS BANCORP INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 12-May-09 09:00AM | ANNAPOLIS BANCORP INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online |
| 27-Apr-09 04:47PM | ANNAPOLIS BANCORP INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit EDGAR Online |
|
|
|
 |
| Market Cap | 357.79M | EPS (ttm) | 1.83 |
| P/E | 14.89 | EPS this Y | -2.67% |
| Forward P/E | 13.42 | EPS next Y | 12.78% |
| PEG | - | EPS past 5Y | -0.63% |
| P/S | 3.67 | EPS next 5Y | - |
| P/B | 1.16 | EPS Q/Q | 121.80% |
| Dividend | 3.30% | Sales Q/Q | 18.40% |
| Insider Own | 20.14% | Inst Own | 48.07% |
| Insider Trans | 0.01% | Inst Trans | 1.45% |
| Short Float | 6.04% | Earnings | Oct 20 |
| Analyst Recom | 3.00 | Target Price | 35.00 |
| Avg Volume | 24.77K | 52W Range | 26.14 - 41.69 |
|
|
|
|
|
 |
| Market Cap | 29.92M | EPS (ttm) | 0.39 |
| P/E | 14.10 | EPS this Y | -10.80% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | 3.52 | EPS next 5Y | - |
| P/B | 1.82 | EPS Q/Q | -46.09% |
| Dividend | - | Sales Q/Q | 1.59% |
| Insider Own | 67.87% | Inst Own | 0.20% |
| Insider Trans | - | Inst Trans | - |
| Short Float | 0.04% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 9.50K | 52W Range | 1.45 - 8.59 |
|
|
|
|
|
 |
| Market Cap | 49.62M | EPS (ttm) | -0.11 |
| P/E | - | EPS this Y | -2.84% |
| Forward P/E | - | EPS next Y | -10.00% |
| PEG | - | EPS past 5Y | 0.00% |
| P/S | 620.31 | EPS next 5Y | - |
| P/B | 8.62 | EPS Q/Q | 6.37% |
| Dividend | - | Sales Q/Q | 0.00% |
| Insider Own | 33.96% | Inst Own | 2.24% |
| Insider Trans | 0.02% | Inst Trans | -57.95% |
| Short Float | 0.09% | Earnings | - |
| Analyst Recom | 1.00 | Target Price | 2.00 |
| Avg Volume | 149.58K | 52W Range | 0.40 - 2.00 |
|
|
| 01-Feb-10 08:00AM | Rexahn Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference Business Wire |
| 19-Jan-10 08:00AM | Rexahn Pharmaceuticals Granted European Patent for Anti-Cancer Compound RX-3117 Business Wire |
| 14-Dec-09 08:00AM | Rexahn and TheraTarget Form Nano Science Research Collaboration Business Wire |
| 20-Nov-09 01:04PM | REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials |
| 17-Nov-09 08:00AM | Rexahn Pharmaceuticals Provides Third Quarter 2009 Business Update Business Wire |
| 16-Nov-09 04:21PM | REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 20-Oct-09 06:01AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online |
| 19-Oct-09 01:36PM | Midday Movers: Pump Up the Volume at TheStreet.com |
| 21-Sep-09 10:54AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ EDGAR Online |
| 10-Aug-09 06:07AM | REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materia EDGAR Online |
|
|
|
 |
| Market Cap | 26.14M | EPS (ttm) | -0.09 |
| P/E | - | EPS this Y | 49.59% |
| Forward P/E | 52.50 | EPS next Y | 128.60% |
| PEG | - | EPS past 5Y | 0.00% |
| P/S | 2.78 | EPS next 5Y | - |
| P/B | 6.18 | EPS Q/Q | 55.29% |
| Dividend | - | Sales Q/Q | 54.06% |
| Insider Own | 36.65% | Inst Own | 5.60% |
| Insider Trans | -2.56% | Inst Trans | 7.73% |
| Short Float | 0.03% | Earnings | Feb 25/b |
| Analyst Recom | 2.00 | Target Price | 3.00 |
| Avg Volume | 44.75K | 52W Range | 0.58 - 1.95 |
|
|
|
|
|
 |
| Market Cap | 16.00M | EPS (ttm) | 0.87 |
| P/E | 1.90 | EPS this Y | 67.19% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 0.39% |
| P/S | 1.63 | EPS next 5Y | - |
| P/B | 3.44 | EPS Q/Q | -102.99% |
| Dividend | 6.32% | Sales Q/Q | -97.85% |
| Insider Own | 8.13% | Inst Own | 2.84% |
| Insider Trans | - | Inst Trans | -689.00% |
| Short Float | 0.10% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 58.34K | 52W Range | 1.51 - 6.54 |
|
|
|
|
|
 |
| Market Cap | 602.03M | EPS (ttm) | 7.03 |
| P/E | 4.20 | EPS this Y | 1410.86% |
| Forward P/E | 12.41 | EPS next Y | 9.68% |
| PEG | - | EPS past 5Y | 79.60% |
| P/S | 4.75 | EPS next 5Y | 0.00% |
| P/B | 1.06 | EPS Q/Q | -101.79% |
| Dividend | 10.22% | Sales Q/Q | -48.52% |
| Insider Own | 4.42% | Inst Own | 15.97% |
| Insider Trans | -50.53% | Inst Trans | -2.40% |
| Short Float | 0.82% | Earnings | Nov 09/b |
| Analyst Recom | 1.80 | Target Price | 31.50 |
| Avg Volume | 217.04K | 52W Range | 11.00 - 32.14 |
|
|
| 09-Feb-10 | Reiterated |
RBC Capital Mkts |
Outperform |
$26 → $31 |
|
|
|
|
|
|
 |
| Market Cap | - | EPS (ttm) | - |
| P/E | - | EPS this Y | - |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | - | EPS Q/Q | - |
| Dividend | 1.80% | Sales Q/Q | - |
| Insider Own | - | Inst Own | - |
| Insider Trans | - | Inst Trans | - |
| Short Float | - | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 5.33K | 52W Range | 13.22 - 25.35 |
|
|
|
|
|
 |
| Market Cap | - | EPS (ttm) | - |
| P/E | - | EPS this Y | - |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | - | EPS Q/Q | - |
| Dividend | 2.36% | Sales Q/Q | - |
| Insider Own | - | Inst Own | - |
| Insider Trans | - | Inst Trans | - |
| Short Float | - | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 8.14K | 52W Range | 15.28 - 25.11 |
|
|
|
|
|
 |
| Market Cap | - | EPS (ttm) | - |
| P/E | - | EPS this Y | - |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | - | EPS Q/Q | - |
| Dividend | 2.26% | Sales Q/Q | - |
| Insider Own | - | Inst Own | - |
| Insider Trans | - | Inst Trans | - |
| Short Float | - | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 28.28K | 52W Range | 18.53 - 41.01 |
|
|
|
|
|
|
1 2 3 4 5 6 ... 10 ... 20 next
|
|
